Literature DB >> 31477497

SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.

David A Hess1, Daniella C Terenzi2, Justin Z Trac3, Adrian Quan4, Tamique Mason3, Mohammed Al-Omran5, Deepak L Bhatt6, Natasha Dhingra4, Ori D Rotstein7, Lawrence A Leiter8, Bernard Zinman9, Sandra Sabongui4, Andrew T Yan10, Hwee Teoh11, C David Mazer12, Kim A Connelly13, Subodh Verma14.   

Abstract

Hess et al. quantified circulating aldehyde dehydrogenase-expressing (ALDHhi) cell subsets in people with T2DM given either empagliflozin (EMPA) or placebo. EMPA treatment increased circulating pro-angiogenic CD133+ progenitor cells, decreased pro-inflammatory ALDHhi granulocyte precursors, and increased ALDHhi monocytes with M2 polarization. EMPA treatment improved T2DM-associated "regenerative cell depletion" contributing to enhanced vascular health.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31477497     DOI： 10.1016/j.cmet.2019.08.015

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


  17 in total

Review 1.  Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease.

Authors:  Tian Gan; Yi Song; Feng Guo; Guijun Qin
Journal:  Mol Biol Rep       Date:  2022-08-24       Impact factor: 2.742

Review 2.  Impact of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging-What Do We Know So Far? (A Narrative Review).

Authors:  Cristina Andreea Adam; Razvan Anghel; Dragos Traian Marius Marcu; Ovidiu Mitu; Mihai Roca; Florin Mitu
Journal:  Life (Basel)       Date:  2022-05-27

3.  Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis.

Authors:  Vinay Garg; Subodh Verma; Kim A Connelly; Andrew T Yan; Aditya Sikand; Ankit Garg; Paul Dorian; Fei Zuo; Lawrence A Leiter; Bernard Zinman; Peter Jüni; Atul Verma; Hwee Teoh; Adrian Quan; C David Mazer; Andrew C T Ha
Journal:  Metabol Open       Date:  2020-06-21

Review 4.  Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.

Authors:  Volker Vallon; Subodh Verma
Journal:  Annu Rev Physiol       Date:  2020-11-16       Impact factor: 19.318

5.  SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.

Authors:  Rhanderson Cardoso; Fabrissio P Graffunder; Caique M P Ternes; Amanda Fernandes; Ana V Rocha; Gilson Fernandes; Deepak L Bhatt
Journal:  EClinicalMedicine       Date:  2021-06-05

Review 6.  Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review.

Authors:  Gary D Lopaschuk; Subodh Verma
Journal:  JACC Basic Transl Sci       Date:  2020-06-22

Review 7.  Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence.

Authors:  Benedetta Maria Bonora; Angelo Avogaro; Gian Paolo Fadini
Journal:  Diabetes Metab Syndr Obes       Date:  2020-01-21       Impact factor: 3.168

Review 8.  Impact of Diabetes Mellitus on Bone Health.

Authors:  Cliodhna E Murray; Cynthia M Coleman
Journal:  Int J Mol Sci       Date:  2019-09-30       Impact factor: 5.923

Review 9.  Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?

Authors:  Ehab Bakbak; Daniella C Terenzi; Justin Z Trac; Hwee Teoh; Adrian Quan; Stephen A Glazer; Ori D Rotstein; Mohammed Al-Omran; Subodh Verma; David A Hess
Journal:  Rev Endocr Metab Disord       Date:  2021-07-06       Impact factor: 6.514

10.  Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.

Authors:  Subodh Verma; Abhinav Sharma; Bernard Zinman; Anne Pernille Ofstad; David Fitchett; Martina Brueckmann; Christoph Wanner; Isabella Zwiener; Jyothis T George; Silvio E Inzucchi; Javed Butler; C David Mazer
Journal:  Diabetes Obes Metab       Date:  2020-03-29       Impact factor: 6.577
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.